| Market Capitalization (Millions $) |
13,067 |
| Shares
Outstanding (Millions) |
121 |
| Employees |
423 |
| Revenues (TTM) (Millions $) |
1,664 |
| Net Income (TTM) (Millions $) |
414 |
| Cash Flow (TTM) (Millions $) |
250 |
| Capital Exp. (TTM) (Millions $) |
12 |
Business Description
Halozyme Therapeutics Inc.
is a biotechnology company based in San Diego, California, whose mission is to develop and commercialize innovative therapies for the treatment of cancer and other chronic diseases.
Founded in 1998, the company is focused on creating novel pharmaceutical products that are designed to improve the lives of patients using its proprietary Enhanze drug delivery technology.
The company has established strategic collaborations with some of the world's leading pharmaceutical companies, including Roche, Pfizer, and Bristol-Myers Squibb.
The company's Enhanze technology platform is based on the use of an enzyme called hyaluronidase, which is designed to break down the extracellular matrix that surrounds tumor cells and other tissues, thereby allowing drugs to diffuse more easily into the target cells.
This approach has been shown to enhance the pharmacokinetics and therapeutic efficacy of a variety of drugs, including monoclonal antibodies and chemotherapy agents.
Halozyme Therapeutics has a robust pipeline of drug candidates that utilize this technology, including several clinical-stage products that are being evaluated in various oncology indications.
One of the company's most promising pipeline candidates is PEGPH20, a recombinant human hyaluronidase enzyme that is being developed for the treatment of pancreatic cancer.
PEGPH20 is currently in Phase III clinical trials, and the company is hoping to demonstrate that it can improve the outcomes for this notoriously difficult-to-treat disease.
In addition to its Enhanze platform, Halozyme Therapeutics is also involved in the development of other novel therapies, including immune-oncology agents and enzyme replacement therapies for rare diseases.
The company has a diverse intellectual property portfolio, with more than 400 issued patents and pending patent applications worldwide.
Overall, Halozyme Therapeutics Inc.
is a leading biotech company that is leveraging its innovative technology platform to develop new and exciting treatments for some of the most challenging diseases facing patients today.
The company has a strong track record of success, having brought several products to market already, and it seems poised to continue to be a major player in the biotech industry in the years to come.
Company Address: 12390 El Camino Real San Diego 92130 CA
Company Phone Number: 794-8889 Stock Exchange / Ticker: NASDAQ HALO
|
12.28% 
114.01 %